Venet D, Rediti M, Maetens M, Fumagalli D, et al. Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clin Cancer Res 2021;27:5607-5618.
PMID: 34321278